Valuation Trading Multiples & Precedent Transactions: Molecular Diagnostics and Genomics Tools Companies
Valuation benchmarks for Molecular Diagnostics and Genomics Tools Companies. Access public trading comps, EV/EBITDA acquisition multiples, and private market data for pitch books and valuation analysis.
1.1 - Molecular Diagnostics and Genomics Tools Companies Market Context & Valuation Drivers
Companies in this public trading comparables set develop and operate genomics tools and molecular diagnostic testing businesses. They generate revenue from sales of sequencing instruments, consumables and reagents, automation systems, and clinical testing services spanning oncology, infectious disease and reproductive health. They are grouped together because their growth drivers, recurring consumables pull-through, test volumes, and regulated clinical workflows create comparable revenue models and valuation benchmarks.
Typical capabilities include next-generation sequencing platforms and targeted panels, high-quality DNA/RNA extraction kits and library prep reagents, liquid handling robots and sample management systems, analytical instruments such as chromatography and mass spectrometry for molecular characterization, gene and peptide synthesis with protein and antibody production services, bioinformatics pipelines and cloud software for data analysis, cryogenic biostorage and laboratory informatics, and clinical genomics testing with accredited laboratory operations.
Primary customers include biopharma and biotech R&D teams, clinical laboratories and healthcare providers, and academic and government research institutions. Valuation hinges on installed base expansion and consumables pull-through, test volume growth and menu breadth, reimbursement coverage in clinical markets, and margin mix across instruments, consumables and services. Investors track revenue growth, recurring revenue percentage, EBITDA margins, and customer retention driven by locked-in workflows and regulatory approvals.
2. Valuation Analysis: Public Trading Comps & Multiples for Molecular Diagnostics and Genomics Tools Companies companies
2.1 - Public Peer Groups & Median Valuation Multiples for Molecular Diagnostics and Genomics Tools Companies sector
Comparable group 1: Molecular Diagnostics and Genomics Tools Companies
MGI Tech
- Enterprise value: $●●●m
- Market Cap: $●●●m
- EV/Revenue: ●.●x
- EV/EBITDA: ●●.●x
- Description: Provider of high-throughput genome sequencing solutions offering genetic sequencers, reagents, and laboratory automation systems to support life sciences and biotechnology research
- Key Products:
- DNBSEQ Sequencers: High-throughput sequencers for diverse genetic applications
- Sequencing Reagents: Comprehensive reagent kits for sequencing processes
- ATOPlex Platform: Advanced platform facilitating targeted sequencing
- Laboratory Automation: Solutions for automated sample processing and library preparation
- DNBelab C Series: Portable single-cell laboratory systems for efficient genomic analysis
Genscript Biotech
- Enterprise value: $●●●m
- Market Cap: $●●●m
- EV/Revenue: ●.●x
- EV/EBITDA: ●●.●x
- Description: Provider of biotechnology solutions for life science research and applications, offering a comprehensive portfolio of services focused on early drug discovery and development, serving researchers and companies globally.
- Key Products:
- Custom Gene Synthesis: Tailored gene synthesis services for research
- Peptide Synthesis: Advanced peptide synthesis for scientific applications
- Protein Services: Comprehensive protein-related services including expression and purification
- Antibody Services: Production and development of custom antibodies
- CRISPR Services: Cutting-edge CRISPR technologies and solutions